Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109

Breast Cancer Research and Treatment

Volumn 124, Issue 1, 2010, Pages 27-38

  Hockla, Alexandra ^a   Radisky, Derek C ^a   Radisky, Evette S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Protease inhibitors; Proteases; Three dimensional culture models; Tumor microenvironment; Tumor reversion

Indexed keywords

APROTININ; CADMIUM 109; MESOTRYPSIN; ONCOPROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL POLARITY; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; UPREGULATION;

ANTIGENS, CD; APROTININ; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL POLARITY; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; RECOMBINANT PROTEINS; RNA INTERFERENCE; SERINE PROTEINASE INHIBITORS; TRANSCRIPTION, GENETIC; TRYPSIN; UP-REGULATION;

EID: 77957716350     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0699-0     Document Type: Article

References (81)

1. ND Rawlings FR Morton AJ Barrett 2006 MEROPS: the peptidase database Nucleic Acids Res 34 D270 D272 1:CAS:528:DC%2BD28XisFyjsQ%3D%3D 10.1093/nar/gkj089 16381862
2. CA Borgono EP Diamandis 2004 The emerging roles of human tissue kallikreins in cancer Nat Rev Cancer 4 876 890 1:CAS:528:DC%2BD2cXptFegtrY%3D 10.1038/nrc1474 15516960
3. MJ Duffy 2004 The urokinase plasminogen activator system: role in malignancy Curr Pharm Des 10 39 49 1:CAS:528:DC%2BD2cXmsVyhsQ%3D%3D 10.2174/1381612043453559 14754404
4. S Netzel-Arnett JD Hooper R Szabo EL Madison JP Quigley TH Bugge TM Antalis 2003 Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer Cancer Metastasis Rev 22 237 258 1:CAS:528:DC%2BD3sXis1CjtL0%3D 10.1023/A:1023003616848 12784999
5. P Nyberg M Ylipalosaari T Sorsa T Salo 2006 Trypsins and their role in carcinoma growth Exp Cell Res 312 1219 1228 1:CAS:528:DC%2BD28Xjs1ajsb8%3D 10.1016/j.yexcr.2005.12.024 16457812
6. Z Sun P Yang 2004 Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression Lancet Oncol 5 182 190 1:CAS:528:DC%2BD2cXhslSktL4%3D 10.1016/S1470-2045(04)01414-7 15003202
7. AS Bhatt A Welm CJ Farady M Vasquez K Wilson CS Craik 2007 Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway Proc Natl Acad Sci USA 104 5771 5776 1:CAS:528: DC%2BD2sXkt1Kgsbk%3D 10.1073/pnas.0606514104 17389401
8. KK Hansen K Oikonomopoulou A Baruch R Ramachandran P Beck EP Diamandis MD Hollenberg 2008 Proteinases as hormones: targets and mechanisms for proteolytic signaling Biol Chem 389 971 982 1:CAS:528:DC%2BD1cXps1OhtbY%3D 10.1515/BC.2008.120 18979623
9. TJ Wilson KC Nannuru M Futakuchi A Sadanandam RK Singh 2008 Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand Cancer Res 68 5803 5811 1:CAS:528:DC%2BD1cXovVCnsLg%3D 10.1158/0008-5472.CAN-07-5889 18632634
10. W Ruf BM Mueller 2006 Thrombin generation and the pathogenesis of cancer Semin Thromb Hemost 32 Suppl 1 61 68 1:CAS:528:DC%2BD28XltFagtLk%3D 10.1055/s-2006-939555 16673267
11. WB Armstrong AR Kennedy XS Wan TH Taylor QA Nguyen J Jensen W Thompson W Lagerberg FL Meyskens Jr 2000 Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial Clin Cancer Res 6 4684 4691 1:CAS:528: DC%2BD3MXotlemsA%3D%3D 11156220
12. AR Kennedy 1998 Chemopreventive agents: protease inhibitors Pharmacol Ther 78 167 209 1:CAS:528:DyaK1cXjsVejurk%3D 10.1016/S0163-7258(98)00010-2 9690817
13. H Kobayashi T Yagyu K Inagaki T Kondo M Suzuki N Kanayama T Terao 2004 Therapeutic efficacy of once-daily oral administration of a Kunitz-type protease inhibitor, bikunin, in a mouse model and in human cancer Cancer 100 869 877 1:CAS:528:DC%2BD2cXhvF2qurw%3D 10.1002/cncr.20034 14770446
14. H Kobayashi M Suzuki Y Hirashima T Terao 2003 The protease inhibitor bikunin, a novel anti-metastatic agent Biol Chem 384 749 754 1:CAS:528:DC%2BD3sXks1Kiu7g%3D 10.1515/BC.2003.083 12817471
15. SB Malkowicz WG McKenna DJ Vaughn XS Wan KJ Propert K Rockwell SH Marks AJ Wein AR Kennedy 2001 Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia Prostate 48 16 28 1:CAS:528:DC%2BD3MXltVOgsr4%3D 10.1002/pros.1077 11391683
16. JB Putnam D Royston AF Chambers S Dunbar JH Lemmer P Norman E Travis AA Vaporciyan S Yang LR Zacharski 2003 Evaluating the role of serine protease inhibition in the management of tumor micrometastases Oncology (Williston Park) 17 9 30 quiz 31-32
17. HH Nguyen I Aronchik GA Brar DH Nguyen LF Bjeldanes GL Firestone 2008 The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing Proc Natl Acad Sci USA 105 19750 19755 1:CAS:528:DC%2BD1cXhsFCltrrI 10.1073/pnas.0806581105 19064917
18. SM Lippman LM Matrisian 2000 Protease inhibitors in oral carcinogenesis and chemoprevention Clin Cancer Res 6 4599 4603 1:CAS:528:DC%2BD3MXotlensQ%3D%3D 11156207
19. J Cuzick 2003 Treatment of DCIS-results from clinical trials Surg Oncol 12 213 219 10.1016/j.suronc.2003.09.001 14998562
20. HJ Senn R Morant 2008 Chemoprevention of breast and prostate cancers: where do we stand? Ann Oncol 19 Suppl 7 vii234 vii237 10.1093/annonc/mdn470 18790958
21. DA Berry KA Cronin SK Plevritis DG Fryback L Clarke M Zelen JS Mandelblatt AY Yakovlev JD Habbema EJ Feuer 2005 Effect of screening and adjuvant therapy on mortality from breast cancer N Engl J Med 353 1784 1792 1:CAS:528:DC%2BD2MXhtFKrtLbN 10.1056/NEJMoa050518 16251534
22. I Jatoi BE Chen WF Anderson PS Rosenberg 2007 Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis J Clin Oncol 25 1683 1690 10.1200/JCO.2006.09.2106 17404367
23. MJ Bissell D Radisky 2001 Putting tumours in context Nat Rev Cancer 1 46 54 1:STN:280:DC%2BD387mvVOhtw%3D%3D 10.1038/35094059 11900251
24. MJ Bissell DC Radisky A Rizki VM Weaver OW Petersen 2002 The organizing principle: microenvironmental influences in the normal and malignant breast Differentiation 70 537 546 10.1046/j.1432-0436.2002.700907.x 12492495
25. F Wang RK Hansen D Radisky T Yoneda MH Barcellos-Hoff OW Petersen EA Turley MJ Bissell 2002 Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts J Natl Cancer Inst 94 1494 1503 1:CAS:528:DC%2BD38XosVans7Y%3D 12359858
26. VM Weaver OW Petersen F Wang CA Larabell P Briand C Damsky MJ Bissell 1997 Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies J Cell Biol 137 231 245 1:CAS:528:DyaK2sXisVKit7s%3D 10.1083/jcb.137.1.231 9105051
27. CC Park H Zhang M Pallavicini JW Gray F Baehner CJ Park MJ Bissell 2006 Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo Cancer Res 66 1526 1535 1:CAS:528: DC%2BD28XpsVegtQ%3D%3D 10.1158/0008-5472.CAN-05-3071 16452209
28. F Wang VM Weaver OW Petersen CA Larabell S Dedhar P Briand R Lupu MJ Bissell 1998 Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology Proc Natl Acad Sci USA 95 14821 14826 1:CAS:528:DyaK1cXotVGmtbc%3D 10.1073/pnas.95.25.14821 9843973
29. GY Lee PA Kenny EH Lee MJ Bissell 2007 Three-dimensional culture models of normal and malignant breast epithelial cells Nat Methods 4 359 365 1:CAS:528:DC%2BD2sXkt1eqsLk%3D 10.1038/nmeth1015 17396127
30. MA Salameh AS Soares A Hockla ES Radisky 2008 Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin J Biol Chem 283 4115 4123 1:CAS:528:DC%2BD1cXhs1WgtLw%3D 10.1074/jbc.M708268200 18077447
31. R Szmola Z Kukor M Sahin-Toth 2003 Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors J Biol Chem 278 48580 48589 1:CAS:528:DC%2BD3sXptlGkt74%3D 10.1074/jbc.M310301200 14507909
32. T Chase Jr E Shaw 1967 p-Nitrophenyl-p′-guanidinobenzoate HCl: a new active site titrant for trypsin Biochem Biophys Res Commun 29 508 514 1:CAS:528:DyaF1cXls1OqtQ%3D%3D 10.1016/0006-291X(67)90513-X 16496527
33. JC Dachsel JP Taylor SS Mok OA Ross KM Hinkle RM Bailey JH Hines J Szutu B Madden L Petrucelli, et al. 2007 Identification of potential protein interactors of Lrrk2 Parkinsonism Relat Disord 13 382 385 10.1016/j.parkreldis. 2007.01.008 17400507
34. N Jessani M Humphrey WH McDonald S Niessen K Masuda B Gangadharan JR Yates III BM Mueller BF Cravatt 2004 Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo Proc Natl Acad Sci USA 101 13756 13761 1:CAS:528:DC%2BD2cXotVygt7g%3D 10.1073/pnas.0404727101 15356343
35. M Egeblad Z Werb 2002 New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 161 174 1:CAS:528:DC%2BD38Xis1KktL8%3D 10.1038/nrc745 11990853
36. J Debnath JS Brugge 2005 Modelling glandular epithelial cancers in three-dimensional cultures Nat Rev Cancer 5 675 688 1:CAS:528: DC%2BD2MXpsleksL0%3D 10.1038/nrc1695 16148884
37. KL Schmeichel MJ Bissell 2003 Modeling tissue-specific signaling and organ function in three dimensions J Cell Sci 116 2377 2388 1:CAS:528: DC%2BD3sXltFemsLc%3D 10.1242/jcs.00503 12766184
38. KR Shaw CN Wrobel JS Brugge 2004 Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis J Mammary Gland Biol Neoplasia 9 297 310 10.1007/s10911-004-1402-z 15838601
39. PA Kenny MJ Bissell 2003 Tumor reversion: correction of malignant behavior by microenvironmental cues Int J Cancer 107 688 695 1:CAS:528:DC%2BD3sXovVGqu7g%3D 10.1002/ijc.11491 14566816
40. H Liu DC Radisky F Wang MJ Bissell 2004 Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells J Cell Biol 164 603 612 1:CAS:528:DC%2BD2cXhsFalsrc%3D 10.1083/jcb.200306090 14769856
41. J Muschler D Levy R Boudreau M Henry K Campbell MJ Bissell 2002 A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells Cancer Res 62 7102 7109 1:CAS:528:DC%2BD38XpsVahtrY%3D 12460932
42. HM Chen KL Schmeichel IS Mian S Lelievre OW Petersen MJ Bissell 2000 AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression Mol Biol Cell 11 1357 1367 1:CAS:528:DC%2BD3cXlt1Wksrk%3D 10749935
43. S Diederichs E Bulk B Steffen P Ji L Tickenbrock K Lang KS Zanker R Metzger PM Schneider V Gerke, et al. 2004 S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer Cancer Res 64 5564 5569 1:CAS:528:DC%2BD2cXmslaltbk%3D 10.1158/0008-5472.CAN-04-2004 15313892
44. B Han M Nakamura I Mori Y Nakamura K Kakudo 2005 Urokinase-type plasminogen activator system and breast cancer (review) Oncol Rep 14 105 112 1:CAS:528:DC%2BD2MXmt1ChtbY%3D 15944776
45. JY Kang M Dolled-Filhart IT Ocal B Singh CY Lin RB Dickson DL Rimm RL Camp 2003 Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer Cancer Res 63 1101 1105 1:CAS:528:DC%2BD3sXhs1agtLw%3D 12615728
46. C Parr G Watkins RE Mansel WG Jiang 2004 The hepatocyte growth factor regulatory factors in human breast cancer Clin Cancer Res 10 202 211 1:CAS:528:DC%2BD2cXkvF2mtg%3D%3D 10.1158/1078-0432.CCR-0553-3 14734471
47. CM Overall EM Tam R Kappelhoff A Connor T Ewart CJ Morrison X Puente C Lopez-Otin A Seth 2004 Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors Biol Chem 385 493 504 1:CAS:528:DC%2BD2cXlslaisbY%3D 10.1515/BC.2004.058 15255181
48. PA Kenny GY Lee CA Myers RM Neve JR Semeiks PT Spellman K Lorenz EH Lee MH Barcellos-Hoff OW Petersen, et al. 2007 The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression Mol Oncol 1 84 96 1:CAS:528:DC%2BD2sXhtlOitbbO 10.1016/j.molonc.2007. 02.004 18516279
49. G Katona GI Berglund J Hajdu L Graf L Szilagyi 2002 Crystal structure reveals basis for the inhibitor resistance of human brain trypsin J Mol Biol 315 1209 1218 1:CAS:528:DC%2BD38XpsVSlug%3D%3D 10.1006/jmbi.2001.5305 11827488
50. GS Cottrell S Amadesi EF Grady NW Bunnett 2004 Trypsin IV, a novel agonist of protease-activated receptors 2 and 4 J Biol Chem 279 13532 13539 1:CAS:528:DC%2BD2cXis1emu70%3D 10.1074/jbc.M312090200 14726524
51. MG Dozmorov RE Hurst DJ Culkin BP Kropp MB Frank J Osban TM Penning HK Lin 2009 Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells Prostate 69 1077 1090 1:CAS:528:DC%2BD1MXos1Wiurw%3D 10.1002/pros.20960 19343732
52. L Yang L Zhang Q Wu DD Boyd 2008 Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets J Biol Chem 283 35295 35304 1:CAS:528: DC%2BD1cXhsVGqt73F 10.1074/jbc.M806965200 18940803
53. T Takeuchi MA Shuman CS Craik 1999 Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue Proc Natl Acad Sci USA 96 11054 11061 1:CAS:528:DyaK1MXmvVCntb4%3D 10.1073/pnas.96.20.11054 10500122
54. K Yamashita K Mimori H Inoue M Mori D Sidransky 2003 A tumor-suppressive role for trypsin in human cancer progression Cancer Res 63 6575 6578 1:CAS:528:DC%2BD3sXosVGgtbg%3D 14583448
55. CJ Marsit C Okpukpara H Danaee KT Kelsey 2005 Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer Mol Carcinog 44 146 150 1:CAS:528:DC%2BD2MXhtVOqsbzO 10.1002/mc.20125 16013053
56. CJ Marsit MR Karagas H Danaee M Liu A Andrew A Schned HH Nelson KT Kelsey 2006 Carcinogen exposure and gene promoter hypermethylation in bladder cancer Carcinogenesis 27 112 116 1:CAS:528:DC%2BD2MXhtlCmsbnM 10.1093/carcin/bgi172 15987713
57. N Normanno A De Luca C Bianco L Strizzi M Mancino MR Maiello A Carotenuto G De Feo F Caponigro DS Salomon 2006 Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366 2 16 1:CAS:528:DC%2BD28Xht1Crs7k%3D 10.1016/j.gene.2005.10.018 16377102
58. JF Flynn C Wong JM Wu 2009 Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer J Oncol 2009 526963 19390622
59. JS Desgrosellier LA Barnes DJ Shields M Huang SK Lau N Prevost D Tarin SJ Shattil DA Cheresh 2009 An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression Nat Med 15 1163 1169 1:CAS:528:DC%2BD1MXhtV2gsbvF 10.1038/nm.2009 19734908
60. Y Zhao R Bachelier I Treilleux P Pujuguet O Peyruchaud R Baron P Clement-Lacroix P Clezardin 2007 Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases Cancer Res 67 5821 5830 1:CAS:528:DC%2BD2sXmsFCqtr8%3D 10.1158/0008-5472.CAN-06-4499 17575150
61. DG Pestov TM Grzeszkiewicz LF Lau 1998 Isolation of growth suppressors from a cDNA expression library Oncogene 17 3187 3197 1:CAS:528: DyaK1MXlsFamsQ%3D%3D 10.1038/sj.onc.1202260 9872334
62. A Killian N Sarafan-Vasseur R Sesboue F Le Pessot F Blanchard A Lamy M Laurent JM Flaman T Frebourg 2006 Contribution of the BOP1 gene, located on 8q24, to colorectal tumorigenesis Genes Chromosomes Cancer 45 874 881 1:CAS:528:DC%2BD28Xotlehu74%3D 10.1002/gcc.20351 16804918
63. JP Bach B Rinn B Meyer R Dodel M Bacher 2008 Role of MIF in inflammation and tumorigenesis Oncology 75 127 133 1:CAS:528:DC%2BD1cXhsVKju7%2FF 10.1159/000155223 18791328
64. KL Meyer-Siegler KA Iczkowski L Leng R Bucala PL Vera 2006 Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells J Immunol 177 8730 8739 1:CAS:528:DC%2BD28Xht1Kitr3N 17142775
65. E Verjans E Noetzel N Bektas AK Schutz H Lue B Lennartz A Hartmann E Dahl J Bernhagen 2009 Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer BMC Cancer 9 230 10.1186/1471-2407-9-230 19602265
66. X Jiang YL Guo ME Bromberg 2006 Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells Thromb Haemost 96 196 201 1:CAS:528:DC%2BD28Xpt1ShsL4%3D 16894464
67. X Jiang S Zhu TS Panetti ME Bromberg 2008 Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells Thromb Haemost 100 127 133 1:CAS:528:DC%2BD1cXhtFeiu73O 18612547
68. HH Versteeg F Schaffner M Kerver LG Ellies P Andrade-Gordon BM Mueller W Ruf 2008 Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice Cancer Res 68 7219 7227 1:CAS:528:DC%2BD1cXhtVCrsL7I 10.1158/0008-5472.CAN-08-0419 18757438
69. P Arora BD Cuevas A Russo GL Johnson J Trejo 2008 Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion Oncogene 27 4434 4445 1:CAS:528: DC%2BD1cXovV2ksbk%3D 10.1038/onc.2008.84 18372913
70. Z Grishina E Ostrowska W Halangk M Sahin-Toth G Reiser 2005 Activity of recombinant trypsin isoforms on human proteinase-activated receptors (PAR): mesotrypsin cannot activate epithelial PAR-1, -2, but weakly activates brain PAR-1 Br J Pharmacol 146 990 999 1:CAS:528:DC%2BD2MXht1Ghu7vE 10.1038/sj.bjp.0706410 16231009
71. M Hashimoto M Ichihara T Watanabe K Kawai K Koshikawa N Yuasa T Takahashi Y Yatabe Y Murakumo JM Zhang, et al. 2004 Expression of CD109 in human cancer Oncogene 23 3716 3720 1:CAS:528:DC%2BD2cXjsV2ntb4%3D 10.1038/sj.onc.1207418 15116102
72. T Sato Y Murakumo S Hagiwara M Jijiwa C Suzuki Y Yatabe M Takahashi 2007 High-level expression of CD109 is frequently detected in lung squamous cell carcinomas Pathol Int 57 719 724 1:CAS:528:DC%2BD2sXhsVelu7bL 10.1111/j.1440-1827.2007.02168.x 17922683
73. JM Zhang M Hashimoto K Kawai Y Murakumo T Sato M Ichihara S Nakamura M Takahashi 2005 CD109 expression in squamous cell carcinoma of the uterine cervix Pathol Int 55 165 169 1:CAS:528:DC%2BD2MXlt1Ois78%3D 10.1111/j.1440-1827.2005. 01807.x 15826242
74. M Hasegawa S Moritani Y Murakumo T Sato S Hagiwara C Suzuki S Mii M Jijiwa A Enomoto N Asai, et al. 2008 CD109 expression in basal-like breast carcinoma Pathol Int 58 288 294 10.1111/j.1440-1827.2008.02225.x 18429827
75. M Lin DR Sutherland W Horsfall N Totty E Yeo R Nayar XF Wu AC Schuh 2002 Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins Blood 99 1683 1691 1:CAS:528:DC%2BD38XhvFyqtbY%3D 10.1182/blood.V99.5.1683 11861284
76. KR Solomon P Sharma M Chan PT Morrison RW Finberg 2004 CD109 represents a novel branch of the alpha2-macroglobulin/complement gene family Gene 327 171 183 1:CAS:528:DC%2BD2cXhsVCkt70%3D 10.1016/j.gene.2003.11.025 14980714
77. LM Coussens B Fingleton LM Matrisian 2002 Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2387 2392 1:CAS:528:DC%2BD38XisFSmtb0%3D 10.1126/science.1067100 11923519
78. B Fingleton 2008 MMPs as therapeutic targets-still a viable option? Semin Cell Dev Biol 19 61 68 1:CAS:528:DC%2BD2sXhsVeqtLbO 10.1016/j.semcdb.2007.06. 006 17693104
79. JA Sparano P Bernardo P Stephenson WJ Gradishar JN Ingle S Zucker NE Davidson 2004 Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196 J Clin Oncol 22 4683 4690 1:CAS:528:DC%2BD2MXhtFKh 10.1200/JCO.2004.08.054 15570070
80. KD Miller W Gradishar L Schuchter JA Sparano M Cobleigh N Robert H Rasmussen GW Sledge 2002 A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer Ann Oncol 13 1220 1224 1:STN:280:DC%2BD38visVeqsw%3D%3D 10.1093/annonc/mdf199 12181245
81. KD Miller TJ Saphner DM Waterhouse TT Chen A Rush-Taylor JA Sparano AC Wolff MA Cobleigh S Galbraith GW Sledge 2004 A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer Clin Cancer Res 10 1971 1975 1:CAS:528:DC%2BD2cXisVGlu78%3D 10.1158/1078-0432.CCR-03-0968 15041714